MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
convertible debt, net of debt...
$195,004K
Proceeds from equity
offering, net of...
$91,592K
Proceeds from exercise of
common stock warrants
$42,061K
Proceeds from note
payable, net of debt...
$27,745K
Proceeds from exercise of
common stock options
$3,485K
Proceeds from employee
stock purchases
$711K
Net cash provided by
financing activities
$360,552K
Canceled cashflow
$46K
Net change in cash
and cash...
$143,188K
Canceled cashflow
$217,364K
Payments for secondary
registration statement costs
$46K
Stock-based compensation
$21,383K
Other accrued
expenses
$15,388K
Amortization of debt issuance
costs and discount
$3,137K
Payment-in-kind interest
$1,104K
Change in accrued
interest income
-$630K
Depreciation
$167K
Accrued clinical trial
costs
$118K
Proceeds from maturities
of investments
$332,507K
Net cash used in
operating activities
-$153,280K
Net cash used in
investing activities
-$64,084K
Canceled cashflow
$41,927K
Canceled cashflow
$332,507K
Net loss
-$177,042K
Purchases of investments
$396,342K
Prepaid clinical trial
costs
$12,127K
Accounts payable
-$3,040K
Other current and
non-current assets
$2,991K
Non-cash operating lease
expense
-$7K
Purchases of property and
equipment
$249K
Back
Back
Cash Flow
source: myfinsight.com
Celcuity Inc. (CELC)
Celcuity Inc. (CELC)